Abstract:Introduction: Nanoparticles have the advantages of improving the solubility of poorly water-soluble drugs, facilitating the drug across biological barriers, and reducing macrophage phagocytosis in pulmonary drug delivery. However, nanoparticles have a small aerodynamic particle size, which makes it difficult to achieve optimal deposition when delivered directly to the lungs. Therefore, delivering nanoparticles to the lungs effectively has become a popular research topic. Methods: Nanoaggregate microparticles were used as a pulmonary drug delivery strategy for the improvement of the bioavailability of cyclosporine A (CsA). The nanoaggregate microparticles were prepared with polyvinyl pyrrolidone (PVP) as the excipient by combining the anti-solvent method and spray drying process. The physicochemical properties, aerodynamic properties, in vivo pharmacokinetics and inhalation toxicity of nanoaggregate microparticles were systematically evaluated. Results: The optimal nanoparticles exhibited mainly spherical shapes with the particle size and zeta potential of 180.52 nm and -19.8 mV. The nanoaggregate microparticles exhibited irregular shapes with the particle sizes of less than 1.6 µm and drug loading (DL) values higher than 70%. Formulation NM-2 as the optimal nanoaggregate microparticles was suitable for pulmonary drug delivery and probably deposited in the bronchiole and alveolar region, with FPF and MMAD values of 89.62% and 1.74 μm. In addition, inhaled NM-2 had C max and AUC0-∞ values approximately 1.7-fold and 1.8-fold higher than oral cyclosporine soft capsules (Neoral®). The inhalation toxicity study suggested that pulmonary delivery of NM-2 did not result in lung function damage, inflammatory responses, or tissue lesions. Conclusion: The novel nanoaggregate microparticles for pulmonary drug delivery could effectively enhance the relative bioavailability of CsA and had great potential for clinical application.

Preparation of Cyclosporine A -Loaded Cubic Nanoparticles and Determination of Encapsulation Efficiency

Pharmacokinetics and Enhanced Oral Bioavailability in Beagle Dogs of Cyclosporine A Encapsulated in Glyceryl Monooleate/Poloxamer 407 Cubic Nanoparticles

Two Novel Freeze-Dried Ph-Sensitive Cyclosporine A Nanoparticles: Preparation, in Vitro Drug Release, and in Vivo Absorption Enhancement Effects

Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration

Solid Self-Nanoemulsifying Cyclosporin A Pellets Prepared by Fluid-Bed Coating: Preparation, Characterization and in Vitro Redispersibility

Preparation and Evaluation of Poly(Ethylene Glycol)–Poly(Lactide) Micelles As Nanocarriers for Oral Delivery of Cyclosporine A

Ocular Delivery of Cyclosporine A Based on Glyceryl Monooleate/poloxamer 407 Liquid Crystalline Nanoparticles: Preparation, Characterization,in Vitrocorneal Penetration and Ocular Irritation

Solid Self-Nanoemulsifying Cyclosporine A Pellets Prepared by Fluid-Bed Coating: Stability and Bioavailability Study

Amphiphilic Poly(L-Aspartic Acid) Copolymer Nanoparticles for Cyclosporine A Delivery

Preparation and in Vitro Study of Solid Dispersions of Cyclosporine A

Microfluidic Preparation of Nanoparticles Using Poly(ethylene Glycol)-distearoylphosphatidylethanolamine for Solubilizing Poorly Soluble Drugs

Enhancement of Oral Bioavailability of Cyclosporine A: Comparison of Various Nanoscale Drug-Delivery Systems.

Cyclosporin A-loaded poly(ethylene glycol)-b-poly(d,l-lactic acid) micelles: preparation, in vitro and in vivo characterization and transport mechanism across the intestinal barrier.

[Preparation of Cyclosporine A Ph Sensitive Nanoparticles and Oral Pharmacokinetics in Rats].

Studies on in Vitro Release of Cyclosporine A-loaded Microspheres

Highly Drug-Loaded Nanoaggregate Microparticles for Pulmonary Delivery of Cyclosporin A

Study on Preparation Conditions for Polylactide Nanoparticles Loaded Cyclosporine A and Its Oral Bioavailability in Rats

Ph-Sensitive Nanoparticles for Improving the Oral Bioavailability of Cyclosporine A.

HPLC-ELSD Method to Determine Encapsulating Efficiency and Loading Capacity of Ginkgolide B in PEG-PLGA Nanoparticles

Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt.

Effect of Surface Modification on the Uptake of Polylactic Acid Nanoparticles Loading Cyclosporine A by Cells in Vitro and on the Body Distribution in Vivo